Selective inhibitors of cyclooxygenase-2 (COX-2) have been shown to be effective anti-inflammatory drugs with reduced gastrointestinal toxicity relative to conventional nonsteroidal anti-inflammatory drugs. However, given the ability of selective COX-2 inhibitors to suppress vascular prostacyclin synthesis, apart from their deleterious action on renal function, we decided to test the effects of the novel COX-2 inhibitor etoricoxib (ETO) on blood pressure (BP) and vascular reactivity.

Normotensive male Wistar rats and spontaneously hypertensive rats (SHRs) received ETO (10 mg/kg, p.o.) once daily for 5 weeks. BP measurements were performed weekly by the tail-cuff method, and at the end of the treatment period the animals had their aortae removed in order to test the *in vitro*responses to both acetylcholine and sodium nitroprusside.

ETO had no effect on the BP levels of normotensive Wistar rats. However, significant elevation of BP was observed in ETO-treated SHRs in comparison with the untreated SHRs (third week, 204.2 ± 5.8 vs 175.8 ± 5.5 mmHg, *P*\< 0.001; fourth week, 206.4 ± 8.9 vs 185.0 ± 3.8 mmHg, *P*\< 0.05; fifth week, 237.4 ± 4.9 vs 209.8 ± 4.0 mmHg, *P*\< 0.001). Norepinephrine-precontracted aorta rings obtained from ETO-treated SHRs also showed a decreased relaxation response to both acetylcholine and sodium nitroprusside *in vitro*in comparison with the untreated SHR group. No ETO-related effects were observed in the *in vitro*reactivity of aorta rings obtained from the normotensive animals.

These preliminary results suggest that the selective COX-2 inhibitor ETO significantly impairs vascular relaxation in SHRs, thus contributing, at least in part, to the significant potentiation of the hypertensive status of these animals.
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